Redirecting the JAK-STAT signal blocks the SARS-CoV-2 replication.
JAK-STAT pathway
SARS-CoV-2
STAT2
genetic code expansion
interferon-β
unnatural amino acid
virus
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
revised:
05
06
2023
received:
07
01
2023
accepted:
05
07
2023
medline:
26
7
2023
pubmed:
25
7
2023
entrez:
25
7
2023
Statut:
ppublish
Résumé
The distinct disease progression patterns of severe acute respiratory syndrome coronavirus clade 2 (SARS-CoV-2) indicate diverse host immune responses. SARS-CoV-2 severely impairs type I interferon (IFN) cell signaling, resulting in uncontrolled late-phase lung damage in patients. For better pharmacological properties, cytokine modifications may sometimes result in a loss of biological activity against the virus. Here, we employed the genetic code expansion and engineered IFN-β, a phase II clinical cytokine with 3-amino tyrosine (IFN-β-A) that reactivates STAT2 expression in virus-infected human cells through JAK/STAT cell signaling without affecting signal activation and serum half-life. This study identified that genetically encoded IFN-β-A might stabilize the protein-receptor complex and trigger JAK-STAT cell signaling, which is a promising modality for controlling SARS-CoV-2 infection.
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e28965Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Pintó RM, Pérez-Rodríguez FJ, Costafreda MI, et al. Pathogenicity and virulence of hepatitis A virus. Virulence. 2021;12(1):1174-1185.
Mogensen TH. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev. 2009;22(2):240-273.
Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805-820.
Saha RP, Sharma AR, Singh MK, et al. Repurposing drugs, ongoing vaccine, and new therapeutic development initiatives against COVID-19. Front Pharmacol. 2020;11:1258.
Sharma A, Tiwari S, Deb MK, Marty JL. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies. Int J Antimicro Ag. 2020;56(2):106054.
Bobrowski T, Chen L, Eastman RT, et al. Synergistic and antagonistic drug combinations against SARS-CoV-2. Mol Ther. 2021;29(2):873-885.
Monk PD, Marsden RJ, Tear VJ, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Resp Med. 2021;9(2):196-206.
Banoun H. Evolution of SARS-CoV-2: review of mutations, role of the host immune system. Nephron. 2021;145(4):392-403.
Chen DY, Khan N, Close BJ, et al. SARS-CoV-2 disrupts proximal elements in the JAK-STAT pathway. J Virol. 2021;95(19):e0086221.
Huang Y, Liu T. Therapeutic applications of genetic code expansion. Synth Syst Biotechnol. 2018;3(3):150-158.
Moroder L, Budisa N. Synthetic biology of protein folding. Chemphyschem. 2010;11(6):1181-1187.
Mukai T, Lajoie MJ, Englert M, Söll D. Rewriting the genetic code. Annu Rev Microbiol. 2017;71:557-577.
Nödling AR, Spear LA, Williams TL, Luk LYP, Tsai YH. Using genetically incorporated unnatural amino acids to control protein functions in mammalian cells. Essays Biochem. 2019;63(2):237-266.
Hankore ED, Zhang L, Chen Y, Liu K, Niu W, Guo J. Genetic incorporation of noncanonical amino acids using two mutually orthogonal quadruplet codons. ACS Synth Biol. 2019;8(5):1168-1174.
Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today. 2015;20(1):122-128.
Lee ACL, Harris JL, Khanna KK, Hong JH. A comprehensive review on current advances in peptide drug development and design. Int J Mol Sci. 2019;20(10):2383.
Vanderschuren K, Arranz-Gibert P, Khang M, et al. Tuning protein half-life in mouse using sequence-defined biopolymers functionalized with lipids. Proc Natl Acad Sci. 2022;119(4):e2103099119. doi:10.1073/pnas.2103099119
Hayashi A, Haruna K, Sato H, et al. Incorporation of halogenated amino acids into antibody fragments at multiple specific sites enhances antigen binding. ChemBioChem. 2021;22(1):120-123.
Hu R, Bekisz J, Schmeisser H, McPhie P, Zoon K. Human IFN-α protein engineering: the amino acid residues at positions 86 and 90 are important for antiproliferative activity. J Immunol. 2001;167(3):1482-1489.
Sambrook J. Molecular Cloning: a Laboratory Manual. 3rd ed. Cold Spring Harbor Laboratory Press; 2001.
Deepankumar K, George A, Krishna Priya G, et al. Next generation designed protein as a photosensitizer for biophotovoltaics prepared by expanding the genetic code. ACS Sustainable Chem Eng. 2017;5(1):72-77.
George A, Indhu M, Ashokraj S, et al. Genetically encoded dihydroxyphenylalanine coupled with tyrosinase for strain-promoted labeling. Bioorg Med Chem. 2021;50:116460.
Hartung HP, Kieseier B, Goodin DS, et al. Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies. J Neuroinflammation. 2012;9:572.
Pandurangan S, Murugesan P, Ramudu KN, Krishnaswamy B, Ayyadurai N. Enhanced cellular uptake and sustained transdermal delivery of collagen for skin regeneration. ACS Applied Bio Materials. 2020;3(11):7540-7549.
Hellinen L, Bahrpeyma S, Rimpelä AK, Hagström M, Reinisalo M, Urtti A. Microscale thermophoresis as a screening tool to predict melanin binding of drugs. Pharmaceutics. 2020;12(6):554.
Khavrutskii L, Yeh J, Timofeeva O, et al. Protein purification-free method of binding affinity determination by microscale thermophoresis. J Vis Exp. 2013;(78):50541. doi:10.3791/50541
Landry ML, Stanat S, Biron K, et al. A standardized plaque reduction assay for determination of drug susceptibilities of cytomegalovirus clinical isolates. Antimicrob Agents Chemother. 2000;44(3):688-692.
Edwards CJ, Welch SR, Chamberlain J, et al. Molecular diagnosis and analysis of Chikungunya virus. J Clin Virol. 2007;39(4):271-275.
Nadgir SV, Hensler HR, Knowlton ER, Rinaldo CR, Rappocciolo G, Jenkins FJ. Fifty percent tissue culture infective dose assay for determining the titer of infectious human herpesvirus 8. J Clin Microbiol. 2013;51(6):1931-1934.
Müller JA, Harms M, Schubert A, et al. Development of a high-throughput colorimetric Zika virus infection assay. Med Microbiol Immunol. 2017;206(2):175-185.
Augustine G, Aarthy M, Thiagarajan H, et al. Self-assembly and mechanical properties of engineered protein based multifunctional nanofiber for accelerated wound healing. Adv Healthcare Mater. 2021;10(8):2001832.
Augustine G, Raghavan S, NumbiRamudu K, et al. Excited state electronic interconversion and structural transformation of engineered red-emitting green fluorescent protein mutant. J Phys Chem B. 2019;123(10):2316-2324.
Dunn GP, Bruce AT, Sheehan KCF, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol. 2005;6(7):722-729.
Burnette BC, Liang H, Lee Y, et al. The efficacy of radiotherapy relies upon induction of type I interferon-dependent innate and adaptive immunity. Cancer Res. 2011;71(7):2488-2496.
Doherty MR, Cheon H, Junk DJ, et al. Interferon-beta represses cancer stem cell properties in triple-negative breast cancer. Proc Natl Acad Sci. 2017;114(52):13792-13797.
Doherty MR, Parvani JG, Tamagno I, et al. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer. Breast Cancer Res. 2019;21(1):54.
Emeny JM, Morgan MJ. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J Gen Virol. 1979;43(1):247-252.
Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 and Novel Therapeutics against Coronavirus (COVID-19). StatPearls Publishing; 2022.
Ethiraj P, Veerappan K, Doraisami B, Sivapatham S. Synergistic anti-carcinogenic effect of interferon-β with cisplatin on human breast adenocarcinoma MDA MB231 cells. Int Immunopharmacol. 2014;23(1):222-228.
Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology. 2007;68(24 suppl 4):S8-S11.
Lundahl MLE, Fogli S, Colavita PE, Scanlan EM. Aggregation of protein therapeutics enhances their immunogenicity: causes and mitigation strategies. RSC Chem Biol. 2021;2(4):1004-1020.
van Beers MMC, Jiskoot W, Schellekens H. On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis. J Interferon Cytokine Res. 2010;30(10):767-775.
Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030.
Wang Q, Parrish AR, Wang L. Expanding the genetic code for biological studies. Chem Biol. 2009;16(3):323-336.
Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575.
Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci. 2010;31(2):53-59.
Chen D, Oezguen N, Urvil P, Ferguson C, Dann SM, Savidge TC. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci Adv. 2016;2(3):e1501240.
Wang Y, Liu M, Gao J. Enhanced receptor binding of SARS-CoV-2 through networks of hydrogen-bonding and hydrophobic interactions. Proc Natl Acad Sci. 2020;117(25):13967-13974.
Bolko L, Jiang W, Tawara N, et al. The role of interferons type I, II and III in myositis: a review. Brain Pathol. 2021;31(3):e12955.
Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HAR. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71-81.
Fink K, Grandvaux N. STAT2 and IRF9: beyond ISGF3. JAK-STAT. 2013;2(4):e27521.
Blaszczyk K, Olejnik A, Nowicka H, et al. STAT2/IRF9 directs a prolonged ISGF3-like transcriptional response and antiviral activity in the absence of STAT1. Biochem J. 2015;466(3):511-524.
Cheng Y, King NJC, Kesson AM. Major histocompatibility complex class I (MHC-I) induction by West Nile virus: involvement of 2 signaling pathways in MHC-I up-regulation. J Infect Dis. 2004;189(4):658-668.
Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44-51.
Abraham S, Nagaraj AS, Basak S, Manjunath R. Japanese encephalitis virus utilizes the canonical pathway to activate NF-κB but it utilizes the type I interferon pathway to induce major histocompatibility complex class I expression in mouse embryonic fibroblasts. J Virol. 2010;84(11):5485-5493.
Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol. 2014;14(1):36-49.
Nan Y, Wu C, Zhang YJ. Interplay between janus kinase/signal transducer and activator of transcription signaling activated by type I interferons and viral antagonism. Front Immunol. 2017;8:1758.
Schneider WM, Chevillotte MD, Rice CM. Interferon-stimulated genes: a complex web of host defenses. Annu Rev Immunol. 2014;32:513-545.
Khan MAAK, Islam ABMMK. SARS-CoV-2 proteins exploit host's genetic and epigenetic mediators for the annexation of key host signaling pathways. Front Mol Biosci. 2021;7:598583.
Kim YM, Shin EC. Type I and III interferon responses in SARS-CoV-2 infection. Exp Mol Med. 2021;53(5):750-760.
Göertz GP, McNally KL, Robertson SJ, Best SM, Pijlman GP, Fros JJ. The methyltransferase-like domain of chikungunya virus nsP2 inhibits the interferon response by promoting the nuclear export of STAT1. J Virol. 2018;92(17):e01008-18. doi:10.1128/jvi.01008-18
V'Kovski P, Kratzel A, Steiner S, Stalder H, Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nat Rev Microbiol. 2021;19(3):155-170.
Grubaugh ND, Hanage WP, Rasmussen AL. Making sense of mutation: what D614G means for the COVID-19 pandemic remains unclear. Cell. 2020;182(4):794-795.
Korber B, Fischer WM, Gnanakaran S, et al. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812-827.
Andreakos E, Tsiodras S. COVID-19: lambda interferon against viral load and hyperinflammation. EMBO Mol Med. 2020;12(6):e12465.